Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > FY2022 Drug Pricing Reform
FY2022 Drug Pricing Reform
-
MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts
March 4, 2022
-
Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
-
Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More
January 19, 2022
-
Chuikyo OKs FY2022 Drug Pricing Reform Outline; Spillover Exclusion, Mega Seller Rule
December 23, 2021
-
Gist of FY2022 Drug Pricing Reform
December 22, 2021
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…